.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A single-center, triple-blind, randomized, placebo-controlled pilot trial evaluated the effect of citicoline on cognitive and functional recovery in 60 adults with mild-to-moderate traumatic brain injury. Patients received citicoline 1000 mg/day or placebo for 90 days. At day 90, patients receiving citicoline demonstrated significantly better cognitive and functional outcomes. Mean MMSE scores were 25.2 versus 21.5 with placebo, while Barthel Index scores were 85.0 versus 70.0 and GOS-E scores were 5.2 versus 3.6; all comparisons had P<0.001. New or worsening intracerebral hemorrhage occurred in 2 patients receiving citicoline and 3 receiving placebo, with no significant difference between groups. The findings suggest that citicoline may improve cognitive and functional recovery following mild-to-moderate TBI, although the authors emphasize that larger multicenter trials are required to confirm these preliminary findings.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A single-center, triple-blind, randomized, placebo-controlled pilot trial evaluated the effect of citicoline on cognitive and functional recovery in 60 adults with mild-to-moderate traumatic brain injury. Patients received citicoline 1000 mg/day or placebo for 90 days. At day 90, patients receiving citicoline demonstrated significantly better cognitive and functional outcomes. Mean MMSE scores were 25.2 versus 21.5 with placebo, while Barthel Index scores were 85.0 versus 70.0 and GOS-E scores were 5.2 versus 3.6; all comparisons had P<0.001. New or worsening intracerebral hemorrhage occurred in 2 patients receiving citicoline and 3 receiving placebo, with no significant difference between groups. The findings suggest that citicoline may improve cognitive and functional recovery following mild-to-moderate TBI, although the authors emphasize that larger multicenter trials are required to confirm these preliminary findings.
last month
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
Last week
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
Last week
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
Last week
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
Last week
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
Last week
